Ajinomoto Co., Inc. has signed a license settlement with Exelixis, Inc. to include AJICAP, Ajinomoto Co.’s proprietary site-specific bioconjugation and linker applied sciences, within the improvement of a few of Exelixis’ antibody-drug conjugate (ADC) packages.
Exelixis is an oncology-focused biotechnology firm seeking to speed up the invention, improvement and commercialization of recent medicines for difficult-to-treat cancers. Using its community of biotherapeutics collaborations, the corporate is creating subsequent technology ADCs for the therapy of varied cancers.
Ajinomoto Co. is a expertise supplier for biopharmaceuticals and the proprietor of CDMO Ajinomoto Bio-Pharma Providers. AJICAP is Ajinomoto Co.’s proprietary site-specific bioconjugation and steady linker applied sciences appropriate with generally used antibody isotypes.
AJICAP expertise consists of its “off-the-shelf” characteristic, permitting any therapeutic antibody at any stage of improvement to be conjugated to drug-payloads of alternative with out the necessity for antibody engineering or cell line improvement, and steady/hydrophilic linkers to generate antibody-drug conjugates with an enhanced therapeutic window.
As a part of the license settlement, Exelixis could have the precise to make use of the AJICAP expertise to help its goal of advancing a number of ADCs with the potential for increased efficacy and decrease toxicity than at present out there choices.
Ajinomoto Co. is eligible to obtain improvement, regulatory and industrial milestone funds in addition to royalties on industrial gross sales.
Tatsuya Okuzumi, basic supervisor, Enterprise Improvement Group, Bio-Pharma Providers Division, Ajinomoto Co., stated: “We’re very excited to help Exelixis, a pacesetter in oncology drug discovery, improvement, and commercialization, within the improvement of novel antibody-drug conjugates. The mixture of Exelixis’ antibodies and payloads with Ajinomoto Co.’s AJICAP opens up a variety of oncology purposes and could also be harnessed to supply a medical profit to sufferers.”
